Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Genomic and Epigenomic Alterations in Cancer.

Chakravarthi BV, Nepal S, Varambally S.

Am J Pathol. 2016 Jul;186(7):1724-35. doi: 10.1016/j.ajpath.2016.02.023. Review.

PMID:
27338107
2.

Histone demethylases in physiology and cancer: a tale of two enzymes, JMJD3 and UTX.

Arcipowski KM, Martinez CA, Ntziachristos P.

Curr Opin Genet Dev. 2016 Feb;36:59-67. doi: 10.1016/j.gde.2016.03.010. Epub 2016 May 3. Review.

PMID:
27151432
3.

Epigenetic Dysfunction in Turner Syndrome Immune Cells.

Thrasher BJ, Hong LK, Whitmire JK, Su MA.

Curr Allergy Asthma Rep. 2016 May;16(5):36. doi: 10.1007/s11882-016-0612-y. Review.

PMID:
27039394
4.

UTX in muscle regeneration - the right dose and the right time.

Liu L, Rando TA.

J Clin Invest. 2016 Apr 1;126(4):1233-5. doi: 10.1172/JCI86798. Epub 2016 Mar 21.

PMID:
26999609
5.

UTX demethylase activity is required for satellite cell-mediated muscle regeneration.

Faralli H, Wang C, Nakka K, Benyoucef A, Sebastian S, Zhuang L, Chu A, Palii CG, Liu C, Camellato B, Brand M, Ge K, Dilworth FJ.

J Clin Invest. 2016 Apr 1;126(4):1555-65. doi: 10.1172/JCI83239. Epub 2016 Mar 21.

6.

Epigenetic modulators, modifiers and mediators in cancer aetiology and progression.

Feinberg AP, Koldobskiy MA, Göndör A.

Nat Rev Genet. 2016 May;17(5):284-99. doi: 10.1038/nrg.2016.13. Epub 2016 Mar 14.

7.

UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia.

Benyoucef A, Palii CG, Wang C, Porter CJ, Chu A, Dai F, Tremblay V, Rakopoulos P, Singh K, Huang S, Pflumio F, Hébert J, Couture JF, Perkins TJ, Ge K, Dilworth FJ, Brand M.

Genes Dev. 2016 Mar 1;30(5):508-21. doi: 10.1101/gad.276790.115.

PMID:
26944678
8.

Targeting EZH2 in cancer.

Kim KH, Roberts CW.

Nat Med. 2016 Feb;22(2):128-34. doi: 10.1038/nm.4036. Review.

PMID:
26845405
9.

Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma.

Xie J, Zhu C, Wu J, Li C, Luo L, Xia L, Li X, Gui Y, Cai Z, Li Z.

Oncotarget. 2016 Feb 9;7(6):6824-34. doi: 10.18632/oncotarget.6829.

10.

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.

Agarwal P, Alzrigat M, Párraga AA, Enroth S, Singh U, Ungerstedt J, Österborg A, Brown PJ, Ma A, Jin J, Nilsson K, Öberg F, Kalushkova A, Jernberg-Wiklund H.

Oncotarget. 2016 Feb 9;7(6):6809-23. doi: 10.18632/oncotarget.6843.

11.

X-chromosome inactivation and escape.

Disteche CM, Berletch JB.

J Genet. 2015 Dec;94(4):591-9.

12.

EZH2 in Bladder Cancer, a Promising Therapeutic Target.

Martínez-Fernández M, Rubio C, Segovia C, López-Calderón FF, Dueñas M, Paramio JM.

Int J Mol Sci. 2015 Nov 13;16(11):27107-32. doi: 10.3390/ijms161126000. Review.

13.

Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas.

Lunning MA, Green MR.

Blood Cancer J. 2015 Oct 16;5:e361. doi: 10.1038/bcj.2015.89. Review.

14.

UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1.

Choi HJ, Park JH, Park M, Won HY, Joo HS, Lee CH, Lee JY, Kong G.

EMBO Rep. 2015 Oct;16(10):1288-98. doi: 10.15252/embr.201540244. Epub 2015 Aug 24.

PMID:
26303947
15.

IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.

Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, Steidl C, Fu K, Li Y, Hung S, Weisenburger DD, Greiner TC, Smith L, Ott G, Rogan EG, Staudt LM, Vose J, Iqbal J, Chan WC.

Blood. 2015 Oct 8;126(15):1741-52. doi: 10.1182/blood-2015-05-644591. Epub 2015 Aug 12.

PMID:
26268241
16.

JMJD3 as an epigenetic regulator in development and disease.

Burchfield JS, Li Q, Wang HY, Wang RF.

Int J Biochem Cell Biol. 2015 Oct;67:148-57. doi: 10.1016/j.biocel.2015.07.006. Epub 2015 Jul 17. Review.

PMID:
26193001
17.

Novel therapeutic strategies for multiple myeloma.

Mimura N, Hideshima T, Anderson KC.

Exp Hematol. 2015 Aug;43(8):732-41. doi: 10.1016/j.exphem.2015.04.010. Epub 2015 Jun 26. Review.

PMID:
26118499
18.

Targeting EZH2 and PRC2 dependence as novel anticancer therapy.

Xu B, Konze KD, Jin J, Wang GG.

Exp Hematol. 2015 Aug;43(8):698-712. doi: 10.1016/j.exphem.2015.05.001. Epub 2015 May 28. Review.

PMID:
26027790
19.

Epigenetic regulation in cancer progression.

Baxter E, Windloch K, Gannon F, Lee JS.

Cell Biosci. 2014 Aug 19;4:45. doi: 10.1186/2045-3701-4-45. eCollection 2014. Review.

20.

The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.

Yang J, AlTahan AM, Hu D, Wang Y, Cheng PH, Morton CL, Qu C, Nathwani AC, Shohet JM, Fotsis T, Koster J, Versteeg R, Okada H, Harris AL, Davidoff AM.

J Natl Cancer Inst. 2015 Apr 29;107(6):djv080. doi: 10.1093/jnci/djv080. Print 2015 Jun.

Items per page

Supplemental Content

Write to the Help Desk